Name: MAC glucuronide linker-2
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

(2S,3R,4S,5S,6S)-2-(2-Amino-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate

IUPAC Name

methyl (2S,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[2-amino-4-(hydroxymethyl)phenoxy]oxane-2-carboxylate

Canonical SMILES

CC(=O)OC1C(C(OC(C1OC(=O)C)OC2=C(C=C(C=C2)CO)N)C(=O)OC)OC(=O)C

InChI

InChI=1S/C20H25NO11/c1-9(23)28-15-16(29-10(2)24)18(30-11(3)25)20(32-17(15)19(26)27-4)31-14-6-5-12(8-22)7-13(14)21/h5-7,15-18,20,22H,8,21H2,1-4H3/t15-,16-,17-,18+,20+/m0/s1

InChIKey

ZAZPQJAJSIUIEY-KVIJGQROSA-N

Solubility

DMSO: 200 mg/ml (43916 mm, need ultrasonic)

Appearance

Solid

Shelf Life

0-4°C for short term (days to weeks), or -20°C for long term (months).

Shipping

Room temperature

Storage

Store at -20 °C, keep in dry and avoid sunlight.

Form

Solid

Biological Activity

MAC glucuronide linker-2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]

MAC glucuronide linker-2 is a versatile chemical linker predominantly used in the design of antibody-drug conjugates (ADCs). This linker is particularly valued for its stability in the bloodstream and its selective cleavage in the tumor microenvironment. The glucuronide moiety allows for the controlled release of cytotoxic drugs, ensuring that the therapeutic agent is released only at the target site, such as cancer cells. This targeted drug delivery helps minimize systemic toxicity while enhancing the effectiveness of the drug against tumors, making MAC glucuronide linker-2 a key component in the development of advanced ADC therapies for cancer treatment.

Another important application of MAC glucuronide linker-2 is in the development of targeted gene therapies. The linker is being explored for its potential to deliver nucleic acid-based therapeutics, such as siRNA or gene-editing tools like CRISPR-Cas9, directly to specific tissues or cells. By using the glucuronide linker, these therapeutic agents can be conjugated to targeting moieties, such as antibodies or peptides, ensuring that the therapeutic material reaches the intended cells. This approach improves the precision and efficiency of gene therapies, reducing off-target effects and enhancing therapeutic outcomes in genetic disorders.

In addition to its applications in ADCs and gene therapy, MAC glucuronide linker-2 is also being studied for its potential use in the delivery of immunomodulatory agents. The linker can be attached to small molecules that modulate the immune response, such as checkpoint inhibitors or cytokines, allowing for their targeted release at sites of inflammation or immune activation. This targeted delivery holds promise in the treatment of autoimmune diseases, inflammatory conditions, and even in enhancing the efficacy of cancer immunotherapies. The use of MAC glucuronide linker-2 for precise delivery of immunomodulatory agents could significantly improve therapeutic outcomes while minimizing unwanted systemic effects.